Two separate concerns have connected losartan to cancer over the past fifteen years, and they are often confused with each other. The first is a pharmacological question: does blocking angiotensin receptors, the mechanism that makes losartan lower blood pressure, also nudge cancer risk upward? The second is a manufacturing problem: some losartan batches were found to contain nitrosamine impurities, which are known carcinogens. Neither concern has led any major medical body to recommend that patients stop taking the drug, but the story behind each one is worth understanding in detail.
The 2010 Meta-Analysis That Sparked the Scare
The worry about ARBs (angiotensin receptor blockers, the drug class losartan belongs to) and cancer traces back to a widely publicized 2010 analysis published in The Lancet Oncology. Pooling data from large randomized trials, the authors reported that patients assigned to receive ARBs had a cancer rate of about 7.2%, compared with 6.0% among controls. The overall risk ratio was 1.08, meaning a small but statistically detectable increase. When the analysis was restricted to trials where cancer had been tracked as a pre-planned endpoint, the signal looked slightly stronger.
1PubMed Central. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trialsThat finding made headlines, but it drew immediate criticism from cardiologists and statisticians. The trials pooled together had not been designed to measure cancer risk. Follow-up periods varied widely, the types of cancers counted were inconsistent across studies, and many trials compared ARBs against placebos rather than against other blood-pressure drugs, making it hard to tell whether the effect was real or an artifact of the comparison group. A subsequent large analysis challenged the conclusions, noting that the modest signal did not hold up once methodological limitations were accounted for.
2PubMed. Use of angiotensin receptor blockers and the risk of cancerWhat the Evidence Looks Like Now
Since 2010, the picture has not gotten clearer so much as it has gotten more complicated. Some analyses have continued to find a small statistical association between ARB use and cancer. A population-based cohort study from Shanghai, for instance, found that ARB users had a roughly 10% higher risk of cancer overall compared with non-users, with somewhat larger elevations for lung and thyroid cancers specifically.
3PubMed Central. Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in ShanghaiA meta-regression analysis looking at cumulative drug exposure argued that the risk of cancer with ARBs, particularly lung cancer, appeared to climb with longer use.
4PubMed Central. Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trialsBut other studies point in the opposite direction. A large population-based cohort study found that regular ARB users actually had a lower overall cancer risk than non-users, with a hazard ratio of 0.8, meaning about a 20% reduction. The same study found an even larger protective association for ACE inhibitors, the closely related drug class.
5PubMed Central. Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort studyAnd a Canadian study that specifically examined the four most common cancers (lung, colorectal, breast, and prostate) in long-term ARB users found no increased rate for any of them compared with people taking diuretics or beta-blockers.
6PubMed Central. Long-term use of angiotensin receptor blockers and the risk of cancerThe honest summary is that the epidemiological evidence is a muddle. Studies disagree, and the ones that do find elevated risk tend to report effect sizes that are small and inconsistent across cancer types. That pattern is exactly what you would expect from confounding and methodological noise rather than from a genuine biological hazard.
The Nitrosamine Contamination Problem
Entirely separate from the pharmacological debate, a manufacturing crisis erupted in 2018 when regulators discovered that some ARB products, including certain losartan formulations, contained nitrosamine impurities. The specific contaminants included NDMA and NDEA, which are classified as probable human carcinogens. These chemicals were not part of the drug’s intended formulation; they were byproducts introduced by changes in production processes that brought amines and nitrogen compounds together under the wrong conditions.
7PubMed Central. Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used MedicationsThe contamination was not limited to losartan. Valsartan was the first ARB recalled, followed by irbesartan, and then certain losartan products. As of more than a year after recalls began, the FDA still had not fully determined the extent of nitrosamine presence across all marketed losartan, irbesartan, azilsartan, and eprosartan products.
8PubMed Central. Current Status of Angiotensin Receptor Blocker RecallsIt is important to separate this from the pharmacological question. Nitrosamine contamination is a quality-control failure, not an inherent property of losartan. A perfectly manufactured losartan tablet does not contain nitrosamines. The risk here was that patients who happened to take affected batches over long periods ingested small but cumulative doses of carcinogens alongside their blood-pressure medication. Regulatory agencies have since tightened testing requirements, and manufacturers have reformulated processes to prevent nitrosamine formation. If you are filling a losartan prescription today at a pharmacy in a country with active regulatory oversight, the product should meet current impurity limits.
How the Recalls Disrupted Patient Care
The recalls had consequences beyond the contamination itself. A study tracking over 86,000 recalled ARB users found that medication switches surged after the recalls. Valsartan users were hit hardest: in the 90 days after the valsartan recall, switching rates jumped dramatically, and by 18 months, more than half of valsartan users had changed medications. Losartan users saw a smaller but still notable disruption, with about 7.6% switching. The study also found an increase in medication gaps exceeding 30 days among patients affected by the recalls.
9PubMed Central. Changes in blood pressure, medication adherence, and cardiovascular-related health care use associated with the 2018 angiotensin receptor blocker recalls and drug shortages among patients with hypertensionThose gaps matter. Uncontrolled blood pressure is a well-established and potent risk factor for heart attack and stroke. If the cancer scare led patients to stop taking their medication without switching to an alternative, the cardiovascular harm from that interruption could easily outweigh any theoretical cancer risk from the drug itself. The study did not find significant changes in uncontrolled blood pressure at the population level, which is reassuring, but individual patients who stopped without a replacement may have fared worse.
Not All ARBs Look the Same in the Data
One wrinkle worth knowing about is that different drugs within the ARB class do not all show the same patterns in cancer-related adverse event reporting. A retrospective analysis of pharmacovigilance data found wide variation: valsartan had the highest reporting odds ratio for neoplasm-related adverse events relative to ACE inhibitors, while candesartan showed essentially no difference. Losartan fell somewhere in between, with a higher reporting ratio than candesartan but lower than valsartan.
10Scientific Reports. Retrospective analysis of neoplasms in patients using angiotensin receptor blockersThese kinds of analyses come with a major caveat. Adverse event databases reflect what gets reported, not necessarily what causes harm. The massive media attention around valsartan and its contamination recalls almost certainly inflated reporting for that drug specifically. Losartan’s numbers may be inflated by the same phenomenon to a lesser degree. This is a well-known limitation of pharmacovigilance data: once a possible link makes the news, both patients and physicians become more likely to report cases they might otherwise have attributed to coincidence.
ACE Inhibitors Versus ARBs
Patients often ask whether switching from losartan to an ACE inhibitor (like lisinopril or enalapril) would be safer from a cancer perspective. The two drug classes target the same hormonal system but at different points: ACE inhibitors block the enzyme that produces angiotensin II, while ARBs block the receptor that angiotensin II activates. A large comparative analysis found that ACE inhibitor users generally had lower odds of developing cancer than ARB users, with about a 15% relative difference overall. But the story was not uniform across cancer types. ACE inhibitor users had lower odds of breast, prostate, melanoma, kidney, and colorectal cancers, but higher odds of lung, bladder, and pancreatic cancers. No significant difference was found for leukemia.
11PLoS One. A comparative analysis of ACE Inhibitors and ARBs as cancer risk factorsThe takeaway is that neither drug class is cleanly “safe” or “risky” when it comes to cancer. The associations shift depending on the cancer type and the population studied. Switching drug classes purely out of cancer concern, without considering which cancers you are most worried about and what your other risk factors are, is not a straightforward improvement. And both drug classes appear safer than untreated high blood pressure.
The Biology Cuts Both Ways
One reason the epidemiological picture is so muddled is that the biology of angiotensin and cancer genuinely points in two directions at once. Angiotensin II, the hormone that losartan blocks, has roles beyond blood pressure regulation. It is involved in cell proliferation, the growth of new blood vessels, and inflammatory signaling, all of which are processes that tumors exploit.
12PubMed. Angiotensin receptors: a new role in cancer?In the tumor microenvironment, the receptor that losartan blocks (known as AT1R) can promote blood vessel growth around tumors, help cancer cells become more invasive, and support an inflammatory milieu that favors tumor progression.
13PubMed. Elucidating the Association Between the Upregulation of Angiotensin Type 1-Receptors and the Development of Gastrointestinal MalignanciesBlocking that receptor, as losartan does, should theoretically interfere with those pro-tumor processes. And indeed, there is a growing body of laboratory research suggesting that losartan has anti-cancer properties. In colorectal cancer models, losartan inhibited cell growth, slowed the cell cycle, reduced tumor blood vessel formation, and suppressed the enzymes that tumors use to invade surrounding tissue.
14PubMed Central. Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancerIn prostate cancer cells, losartan showed an additive killing effect when combined with radiation therapy, reducing cell survival more than radiation alone.
15PubMed. Losartan sensitizes selectively prostate cancer cell to ionizing radiationAnd in pancreatic cancer research, losartan slowed tumor progression and extended survival in animal models by dampening a growth-signaling pathway that is overactive in many pancreatic tumors.
16PLoS ONE. Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ ActivationLosartan as a Potential Cancer Treatment Tool
Perhaps the most striking twist in the losartan-cancer story is that researchers are actively studying losartan not as a cancer risk but as a cancer treatment adjunct. Pancreatic cancer, one of the deadliest malignancies, is notoriously difficult to treat partly because its tumors build up a dense, stiff scaffold of tissue that physically blocks drugs from penetrating. Losartan has been shown to soften this scaffold. In recent preclinical work, losartan pretreatment increased blood vessel perfusion inside pancreatic tumors, allowing therapeutic nanoparticles to penetrate deeper into the tumor. The combination suppressed tumor growth, prolonged survival in animal models, and reduced toxicity from standard chemotherapy.
17PubMed. Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapyLosartan also appears to reshape the immune landscape inside tumors. By blocking AT1R, it can shift immune cells from tumor-supporting states to tumor-fighting ones and improve the infiltration of cancer-killing T cells into the tumor interior. These findings are still in early stages, mostly in animal models and cell cultures, but clinical trials combining losartan with standard cancer treatments are underway for several tumor types. It is an odd position for a drug that the public associates with cancer risk to simultaneously be investigated as a cancer-fighting tool, but the biology supports both possibilities depending on context.
What Medical Guidelines Actually Recommend
Despite the headlines, no major cardiovascular or oncology guideline recommends that patients stop or avoid losartan because of cancer concerns. A review in the European Cardiology Review concluded that interrupting successful blood-pressure therapy with ARBs to avoid a generic cancer risk is not justified by current evidence, and recommended watchful waiting with attention to patients who have elevated cancer risk for other reasons.
18European Cardiology Review. Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?This position makes sense given the balance of evidence. The epidemiological associations, where they exist, are small, inconsistent, and not clearly separable from confounding. The nitrosamine contamination problem was real but has been addressed through regulatory action. And the cardiovascular benefits of well-controlled blood pressure are large and well-established. For most patients, the risk of stopping or switching a blood-pressure medication that is working well far exceeds any plausible cancer risk from the drug itself.
When the Question Still Matters
There are situations where the cancer question deserves more attention. If you have a personal or strong family history of lung cancer, the fact that some studies find a modest signal specifically for lung cancer with ARBs is worth discussing with your doctor. Not because the evidence is strong enough to demand a switch, but because it may tip the balance toward an ACE inhibitor or a different drug class, especially if you have other lung cancer risk factors like a smoking history. Similarly, if you were taking a recalled batch of losartan or valsartan for several years before the contamination was caught, it is reasonable to mention that exposure history at your next checkup, even though the absolute risk from the impurity levels found in most contaminated batches was estimated to be very small.
For the vast majority of people taking losartan for high blood pressure or heart failure, the current evidence does not warrant switching medications. The drug has decades of cardiovascular data behind it, and the cancer signal in the literature is too inconsistent and too small to outweigh those benefits. If you are anxious about it, a conversation with your prescriber is more productive than stopping the drug on your own, because uncontrolled blood pressure carries risks that are neither theoretical nor small.